Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3

Methodology|Interests|Funding|Corrections

Finding aid

Document registry — page 2

Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.

Documents

1,621 documents · page 2 of 41

Bibliographic record: OZEMPIC (semaglutide) injection, for subcutaneous use — Highlights of Prescribing…

CEI-BR-023Bibliographic record2026-q3

FDA Approved Labeling 2024

30 Jul 2026
Bibliographic record: Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or…

CEI-BR-024Bibliographic record2026-q3

FDA Guidance 2013

30 Jul 2026
Bibliographic record: WEGOVY (semaglutide) injection, for subcutaneous use — Highlights of Prescribing…

CEI-BR-025Bibliographic record2026-q3

FDA Approved Labeling 2024

30 Jul 2026
Bibliographic record: ZEPBOUND (tirzepatide) injection, for subcutaneous use — Highlights of Prescribing…

CEI-BR-026Bibliographic record2026-q3

FDA Approved Labeling 2024

30 Jul 2026
Bibliographic record: Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes

CEI-BR-027Bibliographic record2026-q3

New England Journal of Medicine 2021

30 Jul 2026
Bibliographic record: Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly…

CEI-BR-028Bibliographic record2026-q3

The Lancet 2023

30 Jul 2026
Bibliographic record: Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre…

CEI-BR-029Bibliographic record2026-q3

The Lancet 2023

30 Jul 2026
Bibliographic record: Thymosin α1 and cancer: action on immune effector and tumor target cells

CEI-BR-030Bibliographic record2026-q3

Annals of the New York Academy of Sciences 2007

30 Jul 2026
Bibliographic record: Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

CEI-BR-031Bibliographic record2026-q3

Nature Medicine 2022

30 Jul 2026
Bibliographic record: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes…

CEI-BR-032Bibliographic record2026-q3

The Lancet 2023

30 Jul 2026
Bibliographic record: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind…

CEI-BR-033Bibliographic record2026-q3

The Lancet 2019

30 Jul 2026
Bibliographic record: Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

CEI-BR-034Bibliographic record2026-q3

New England Journal of Medicine 2021

30 Jul 2026
Bibliographic record: Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical…

CEI-BR-035Bibliographic record2026-q3

Expert Opinion on Biological Therapy 2012

30 Jul 2026
Bibliographic record: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

CEI-BR-036Bibliographic record2026-q3

BMJ 2008

30 Jul 2026
Bibliographic record: GRADE guidelines: 8. Rating the quality of evidence — indirectness

CEI-BR-037Bibliographic record2026-q3

Journal of Clinical Epidemiology 2011

30 Jul 2026
Bibliographic record: GRADE guidelines: 6. Rating the quality of evidence — imprecision

CEI-BR-038Bibliographic record2026-q3

Journal of Clinical Epidemiology 2011

30 Jul 2026
Bibliographic record: The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism…

CEI-BR-039Bibliographic record2026-q3

Endocrinology 2001

30 Jul 2026
Bibliographic record: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and…

CEI-BR-040Bibliographic record2026-q3

The Lancet 2018

30 Jul 2026
Bibliographic record: Measuring inconsistency in meta-analyses

CEI-BR-041Bibliographic record2026-q3

BMJ 2003

30 Jul 2026
Bibliographic record: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight…

CEI-BR-042Bibliographic record2026-q3

Diabetes Care 2003

30 Jul 2026
Bibliographic record: Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

CEI-BR-043Bibliographic record2026-q3

New England Journal of Medicine 2017

30 Jul 2026
Bibliographic record: Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

CEI-BR-044Bibliographic record2026-q3

New England Journal of Medicine 2019

30 Jul 2026
Bibliographic record: ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in…

CEI-BR-045Bibliographic record2026-q3

ICH Harmonised Guideline 2023

30 Jul 2026
Bibliographic record: ICH Q1A(R2) Stability Testing of New Drug Substances and Products

CEI-BR-046Bibliographic record2026-q3

ICH Harmonised Tripartite Guideline 2003

30 Jul 2026
Bibliographic record: ICH Q2(R2) Validation of Analytical Procedures

CEI-BR-047Bibliographic record2026-q3

ICH Harmonised Guideline 2023

30 Jul 2026
Bibliographic record: ICH Q3C(R9) Impurities: Guideline for Residual Solvents

CEI-BR-048Bibliographic record2026-q3

ICH Harmonised Guideline 2024

30 Jul 2026
Bibliographic record: ICH Q6B Specifications: Test Procedures and Acceptance Criteria for…

CEI-BR-049Bibliographic record2026-q3

ICH Harmonised Tripartite Guideline 1999

30 Jul 2026
Bibliographic record: ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration…

CEI-BR-050Bibliographic record2026-q3

ISO/IEC Standard 2017

30 Jul 2026
Bibliographic record: Tirzepatide once weekly for the treatment of obesity

CEI-BR-051Bibliographic record2026-q3

New England Journal of Medicine 2022

30 Jul 2026
Bibliographic record: Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial

CEI-BR-052Bibliographic record2026-q3

New England Journal of Medicine 2023

30 Jul 2026
Bibliographic record: Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and…

CEI-BR-053Bibliographic record2026-q3

European Journal of Pharmaceutical Sciences 2017

30 Jul 2026
Bibliographic record: Efficacy and safety of mazdutide in Chinese participants with overweight or obesity: a…

CEI-BR-054Bibliographic record2026-q3

Diabetes, Obesity and Metabolism 2023

30 Jul 2026
Bibliographic record: Semaglutide once a week in adults with overweight or obesity, with or without type 2…

CEI-BR-055Bibliographic record2026-q3

The Lancet Diabetes & Endocrinology 2022

30 Jul 2026
Bibliographic record: LC–MS bioanalysis of intact proteins and peptides

CEI-BR-056Bibliographic record2026-q3

Biomedical Chromatography 2020

30 Jul 2026
Bibliographic record: Quality of peptide products obtained from unregulated online suppliers: an analytical…

CEI-BR-057Bibliographic record2026-q3

Journal of Pharmaceutical Sciences 2024

30 Jul 2026
Bibliographic record: Peptides and CCL11 and HMGB1 as differently expressed age-dependent proinflammatory…

CEI-BR-058Bibliographic record2026-q3

Advances in Gerontology 2020

30 Jul 2026
Bibliographic record: Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1)…

CEI-BR-059Bibliographic record2026-q3

The Lancet 2023

30 Jul 2026
Bibliographic record: Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable…

CEI-BR-060Bibliographic record2026-q3

Journal of Medicinal Chemistry 2000

30 Jul 2026
Bibliographic record: Semaglutide in patients with heart failure with preserved ejection fraction and obesity

CEI-BR-061Bibliographic record2026-q3

New England Journal of Medicine 2023

30 Jul 2026
Bibliographic record: Semaglutide in patients with obesity-related heart failure and type 2 diabetes

CEI-BR-062Bibliographic record2026-q3

New England Journal of Medicine 2024

30 Jul 2026

page 2 of 41

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.